ArticleJournal of neurology2010
Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).
Article in Journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.Journal of neurology · 2022Pooled it
- Methods of estimating prevalence of multiple sclerosis in six European healthcare data sources: a contribution from the ConcePTION project.European journal of epidemiology · 2026Article
- A Cross-Sectional Study of Delayed Diagnosis Associated with Gender and Racial Identity in Multiple Sclerosis.Journal of racial and ethnic health disparities · 2025Article
- Multiple sclerosis patients' journey delay in diagnosis and treatment: a multicenter study.BMC neurology · 2025Observational
- Albumin and multiple sclerosis: a prospective study from UK Biobank.Frontiers in immunology · 2024Article
- Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Factors associated with the number of months of delaying in multiple sclerosis diagnosis: Comparison of count regression models.Current journal of neurology · 2023Article
- Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients.Scientific reports · 2023Article
- Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age.EBioMedicine · 2022Article
- Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis ofFrontiers in neurology · 2021Article
- Hindsight is 20/20.Journal of hospital medicine · 2020Article
- How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Observational
- Social value of a set of proposals for the ideal approach of multiple sclerosis within the Spanish National Health System: a social return on investment study.BMC health services research · 2020Article
- Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes.Journal of clinical medicine · 2019Review
- Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use.Multiple sclerosis international · 2019Review
- Article
- The tension between early diagnosis and misdiagnosis of multiple sclerosis.Nature reviews. Neurology · 2017Review
- Early recognition of multiple sclerosis using natural language processing of the electronic health record.BMC medical informatics and decision making · 2017Article
- The Prevalence of Bipolar Disorders and Association With Quality of Life in a Cohort of Patients With Multiple Sclerosis.The Journal of neuropsychiatry and clinical neurosciences · 2017Article
- Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study.Neuropsychiatric disease and treatment · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a disease supposedly of autoimmune origin, with reactivity directed against myelin antigens. From the neuropathological point of view, MS produces inflammation, demyelination and axonal and neuronal degeneration. Inflammatory phenomena are predominant in the initial phase of the disease, followed later by neurodegenerative processes. Over the last decade, early treatment, during the most inflammatory phase of the disease, has been considered the best strategy to treat MS. Accordingly, we decided to determine the periods of delay between the first symptoms and the time to the first medical visit, the time to referral to a specialised MS unit, the delay in undertaking clinical and paraclinical tests, the diagnostic criteria used and the overall delay in diagnosis and treatment. The median time from onset of first symptoms to the first visit to a physician was 19.2 months, which represented the greatest delay. The median time between this initial medical consultation and the confirmation of the diagnosis by a specialised MS unit was 5.7 months, and the overall time from symptom onset to diagnosis was 24.9 months (2.08 years). The median time between onset of the first symptoms and the decision to give the first treatment was 2 years. The most important delay was that from symptom onset to the first medical visit, with the other delays being less. Thus, it is during this initial period that greater effort is required in order to reduce the time to diagnosis, by increasing awareness of the problem of MS among the general population and primary care physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.